Effects of Gum Arabic Supplementation in Hemodialysis Patients

Study of Some Pharmacological and Biochemical Effects of Gum Arabic Supplementation to Hemodilaysis Patients

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03789708

Enrollment

Registered

2018-12-31

Start date

2018-11-01

Completion date

2019-06-01

Last updated

2019-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Failure, Chronic

Brief summary

Gum Arabic is a naturally produced gummy exudate from Acacia Senegal tree. It's a complex polysaccharide with proven prebiotic properties. Through its effect on intestinal bacteria, it's expected to reduce systemic levels of toxic bacterial metabolites and reduce inflammatory markers.By increasing fecal bacteria mass it's also expected to reduce blood urea level. These changes are potentially beneficial to hemodialysis patients who suffer from disturbed intestinal flora and a chronic inflammatory status. The investigators hypothesize that supplementing the diet of hemodialysis patients with Gum Arabic for four weeks would reduce inflammatory markers, increase total anti-oxidant capacity and reduce blood urea concentration.

Interventions

DIETARY_SUPPLEMENTGum Arabic

Instantly soluble granules of Gum Arabic; 100% Acacia Senegal

OTHERPlacebo

Maltodextrin powder, easily soluble

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Masking description

The placebo and the Gum Arabic are provided to patients in similar unlabeled packages

Intervention model description

Randomized and controlled clinical trial with parallel design

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult end-stage renal disease patients maintained on regular hemodialysis

Exclusion criteria

* Chronic liver disease * Malignant condition * Inflammatory bowel disease * History of bowel resection * Long term antibiotic therapy * Pregnancy or lactation * Current use of immunosuppressive medication

Design outcomes

Primary

Measure	Time frame	Description
Highly sensitive C-reactive protein (hs CRP) level	4 weeks	Change in serum level of highly sensitive C-reactive protein.
Total anti-oxidant capacity	4 weeks	Change in serum total anti-oxidant capacity
Blood urea level	4 weeks	Change in urea blood level

Secondary

Measure	Time frame	Description
Serum calcium	4 weeks	Change in serum calcium level
Serum phosphorus	4 weeks	Change in serum phosphorus level
Serum uric acid	4 weeks	Change in serum uric acid level

Countries

Sudan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026